publication-iconPhase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins (Tussey et al 2016 PDF)

publication-iconA rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of Influenza B globular head vaccines (Song et al 2014 PDF)

publication-iconDevelopment of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response (Taylor VAX128 Vaccine 2012 PDF)

publication-iconInduction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI) (Taylor Elderly TLR study. Vaccine. 2011 PDF)

publication-iconSafety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults (Treanor et al. 2010 VAX125 PDF)

publication-iconSafety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults (Turley 2011 M2e trial PDF)

publication-iconVaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity  (Huleutt et al 2007 OVA model PDF)

publication-iconEfficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs (Song et al 2008 PDF)

publication-iconSuperior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin (Song et al 2009 PDF)

publication-iconFlagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections ( Liu et al 2012 PDF)

publication-iconImmunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in Mice  (Liu et al 2011 PDF)

publication-iconPotent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin  (Huleutt et al 2008 M2e mouse PDF)

publication-iconAntibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutin Receptor Binding Site (Wilson et al 2013 H1N1 RBD Ab PDF)

publication-iconA West Nile Virus Recombinant Protein Vaccine That Coactivates Innate and Adaptive Immunity (McDonald 2007 West Nile PDF)